PMC9893996_01
PMC9893996_02
PET scan December 2018 demonstrating recurrent unresectable metastatic disease in mediastinum (left) and flank (right). PET, positron emission tomography.
cro-2023-0016-0001-528743_f1.jpg
PMC9893996_02_cro-2023-0016-0001-528743_f1.jpg
F1
At the end of 2018, a positron emission tomography scan identified unresectable recurrence in the mediastinum and left flank (shown in Fig. 1).
PMC9893996_03
PMC9893996_04
PMC9893996_05
Radiological response with trametinib in perinephric/retroperitoneal lesions and mediastinal lesion at month 2 (a, b), 4 (c, d), and 7 (e, f).
cro-2023-0016-0001-528743_f2.jpg
PMC9893996_05_cro-2023-0016-0001-528743_f2.jpg
F2
Computerized tomography scans at month 2, 4, and 7 after commencement of trametinib showed response in all known sites of disease, retroperitoneal/perinephric lesion and mediastinal lesion (shown in Fig. 2).
PMC9893996_06
PMC9893996_07
Summary of systemic treatment in incurable setting for patient and times to progression.
cro-2023-0016-0001-528743_f3.jpg
PMC9893996_07_cro-2023-0016-0001-528743_f3.jpg
F3
In summary, the patient achieved response to disease at all sites on trametinib for 10 months, the most durable response of all his systemic treatments (shown in Fig. 3).